biogen stock nasdaq

Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ: ... For Biogen, a company whose stock is down 17% year to date, it … The business had revenue of $2.85 billion for the quarter, compared to analysts' expectations of $2.80 billion. Alliancebernstein L.P. boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. Davidson & CO. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. , Biogen Stock: Why A Key Medicine Could Shoot To Blockbuster Status By 2025. W e believe that Biogen stock (NASDAQ: BIIB), a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. Stock analysis for Biogen Inc (BIIB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Alliancebernstein L.P. boosted its holdings in Biogen Inc. (NASDAQ:BIIB) by 2.2% during the 4th quarter, according to its most recent disclosure with the SEC. What is Biogen's Market Cap? Valuation. Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Sawtooth Solutions LLC’s holdings in Biogen were worth $1,661,000 as of its most recent SEC filing. M&T Bank Corp’s holdings in Biogen … Analysts Expect Approval. Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Which company executives are buying and selling shares of Biogen (NASDAQ:BIIB) stock? Tecfidera generic competition will worsen in 2021. QQQ 310.88. NASDAQ:BIIB - Biogen Stock Price Target and Predictions. Get the latest Biogen Inc. BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; FAQ; Consensus Rating: Hold; Consensus Price Target: $304.47; Forecasted Upside: 14.25 %; Number of Analysts: 32; Breakdown: 5 Sell Ratings; 15 Hold Ratings; 12 Buy Ratings; 0 Strong Buy Ratings $ 266.49 As of 03/9/2021 01:00 AM ET -3.52 (-1.30%) 1 … Is Biogen Inc. (NASDAQ:BIIB) Trading At A 43% Discount? Get the latest Biogen Inc (BIIB) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The average Biogen stock price prediction forecasts a potential downside of N/A from the current BIIB share price of $263.57. All rights reserved. © 2021 Verizon Media. But if you pay close attention, you might gather that its strong financials could mean … Biogen's stock is trading at a price-to-earnings (P/E) ratio of 11, which is cheap compared to the Health Care Select Sector SPDR Fund, where the average holding trades at a P/E of 25. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Shares fell 1.3% to 266.49 on today's stock market. Find the latest historical data for Biogen Inc. Common Stock (BIIB) at Nasdaq.com. Biogen Inc Stock Dividend Yield & Dates Add to Watchlist. Biogen (NASDAQ:BIIB) Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock … The stock, trading at around $280 this week, has traded between $223.25 and $363.92 over the past 52 weeks. The U.S. Food and Drug Administration (FDA) will soon decide the fate of the company's investigational Alzheimer's drug. Free forex prices, toplists, indices and lots more. Biogen (NASDAQ:BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. What is Biogen … View BIIB's most recent analyst ratings, analyst estimates and price targets at MarketBeat. Biogen (NASDAQ:BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. Competitors Biogen (NASDAQ:BIIB) Vs. AMGN, GILD, VRTX, REGN, ALXN, and SGEN. Is Biogen undervalued compared to its fair value and its price relative to the market? The average number of shares traded each day over the past 30 days, The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks, The ratio of annual dividend to current share price that estimates the dividend return of a stock, A score provided by CDP (formerly the Carbon Disclosure Project) that rates a company on its climate transparency and performance. Biogen stock was originally listed at a price of $5.73 in Dec 31, 1997 . Twin Capital Management Inc. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 2.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange … Biogen Dividends FAQ. The firm owned 6,785 shares of the biotechnology company’s stock after selling 4,149 shares during the quarter. Man sues Hertz over receipt that cleared him of murder. Biogen historical daily return volatility represents how much Biogen stock's price daily returns swing around its mean daily price change - it is a statistical measure of its dispersion of returns. The biotechnology company reported $4.58 earnings per share for the quarter, missing the consensus estimate of $4.87 by ($0.29). S&P 500 3,939.34 (+1.04%) Veritable L.P. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 12.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. Biogen (BIIB) stock price, charts, trades & the US's most popular discussion forums. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Biogen (NASDAQ: BIIB) does not pay a dividend. The company inherits 1.8194% risk (volatility on return distribution) over the 30 days horizon. Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, February, 2nd. Find the latest analyst research for Biogen Inc. Common Stock (BIIB) at Nasdaq.com. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock … 3 weeks ago | Simply Wall St Jesus Mantas Is The Independent Director of Biogen Inc. (NASDAQ:BIIB) And They Just Picked Up 44% More Shares What is Biogen's Dividend Payment Date? S&P 500 3,898.81. With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). The fund owned 70,440 shares of the biotechnology company’s stock after selling 3,785 shares during the period. View Biogen Inc. BIIB investment & stock information. MUFG Americas Holdings Corp’s holdings in Biogen were worth $1,133,000 at the end of the most […] Rating Action: Moody's assigns Ba3 to Alkermes' term loan; stable outlookGlobal Credit Research - 08 Mar 2021New York, March 08, 2021 -- Moody's Investors Service ("Moody's") assigned a Ba3 rating to the new senior secured term loan of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). [7] In May 2006, the company announced it would acquire … The firm owned 276,975 shares of the biotechnology company’s stock after buying an additional 5,955 shares during the period. Veritable L.P.’s holdings in Biogen were worth $1,007,000 as of […] What is BIIB's earnings growth forecast for 2021-2023? Should You Use Biogen's (NASDAQ:BIIB) Statutory Earnings To Analyse It? The institutional investor owned 4,629 shares of the biotechnology company’s stock after acquiring an additional 2,010 shares during the period. Shares have lost about 1.4% in that time frame, outperforming the S&P 500. Two drug companies that have made brain science their mission -- Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ: SAGE)-- announced on … Citi Research analyst Mohit Bansal downgraded Biogen stock (ticker: BIIB) to Sell from Neutral, and set a new target price of $240. Veritable L.P. trimmed its holdings in Biogen Inc. (NASDAQ:BIIB) by 12.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. There are no changes to Alkermes' existing ratings including the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, Ba3 (LGD3) senior secured rating, or the SGL-1 Speculative Grade Liquidity Rating. Biogen (NASDAQ:BIIB) last issued its earnings results on Tuesday, February 2nd. D.A. Back in June, a judge invalidated a patent on Tecfidera, which is the biotech's … :) The Oracle of Omaha picked up 648,447 shares of Biogen , allocating 0.08% of the equity portfolio to the holding. But Clarivate analysts … Biogen (NASDAQ:BIIB) last released its earnings results on Tuesday, February 2nd. View real-time stock prices and stock quotes for a full financial overview. What is the 52 week high and low for Biogen (NASDAQ: BIIB)? The difference between the high and low prices over the past day, The difference between the high and low prices over the past 52 weeks. :) The Oracle of Omaha picked up 648,447 shares of Biogen , allocating 0.08% of the equity portfolio to the holding. It is currently -26.77% from its 52-week high and 19.37% from its 52-week low. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. Davidson & CO. lessened its position in shares of Biogen Inc. (NASDAQ:BIIB) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. By contrast, DOW inherits 0.8185% risk (volatility on return distribution) over the 30 days horizon. The news comes days before the company is scheduled to release further data on a potential Alzheimer’s disease therapy, called donanmeab. During the quarter, the stock traded for an average price of $279.04 per share. Biogen revenue declined rapidly in Q4 2020. (NASDAQ: BIIB) Biogen's 52-week high was $363.92, and its 52-week low was $223.25. With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). Biogen had a net margin of 35.63% and a return on equity of 51.00%. You can buy Biogen cheaper than Warren Buffett did! Biogen Inc. Common Stock (BIIB) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Biogen had a net margin of 35.63% and a return on equity of … GE, AerCap join air leasing businesses in $30 billion deal. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. M&T Bank Corp lowered its position in shares of Biogen Inc. (NASDAQ:BIIB) by 5.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. The fund owned 786 shares of the biotechnology company’s stock after purchasing an additional 120 shares during the […] Get the latest Biogen Inc. BIIB detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The firm owned 276,975 shares of the biotechnology company’s stock after buying an additional 5,955 shares during the period. (NASDAQ: BIIB) Biogen stock price per share is $266.49 today (as of Mar 9, 2021). BIIB | Complete Biogen Inc. stock news by MarketWatch. The biotechnology company reported $4.58 EPS for the quarter, missing the Zacks' consensus estimate of $4.87 by ($0.29). Currency in USD, Trade prices are not sourced from all markets. The fund owned 2,175 shares of the biotechnology company’s stock … DOW 32,297.02. No, BIIB has not paid a dividend within the past 12 months. The biotechnology company reported $4.58 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $4.87 by ($0.29). View real-time stock prices and stock quotes for a full financial overview. The biotechnology company had revenue of $2.85 billion for the quarter, compared to analyst estimates of $2.80 billion. Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, February, 2nd. NASDAQ:BIIB - Biogen Stock Price Target and Predictions. Overview Forecast Earnings Dividend. BIIB | Complete Biogen Inc. stock news by MarketWatch. The institutional investor owned 4,113 shares of the biotechnology company’s stock after selling 599 shares during the period. The biotechnology company reported $4.58 earnings per share for the quarter, missing the Zacks' consensus estimate of … Investors who bought shares of Biogen (NASDAQ:BIIB) in 2010 or earlier and held onto them have plenty of reason to smile; Biogen has gained more than 390% since 2010. Subscribe to Premium to view Fair Value for BIIB. … The fund owned 2,175 shares of the biotechnology company’s stock after selling 301 shares during the quarter. Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. A controversial Alzheimer's drug that has weighed on Biogen stock this year could ultimately become a major blockbuster within five years, a market research group predicted Tuesday. Stock analysis for Biogen Inc (BIIB:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. You can buy Biogen cheaper than Warren Buffett did! How much is Biogen's dividend? Biogen (NASDAQ:BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. View the most recent insider trading activity for BIIB stock at MarketBeat. Biogen had a return on equity of 51.00% and a net margin of 35.63%. It has been about a month since the last earnings report for Biogen Inc. (BIIB). Biogen (NASDAQ:BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. Biogen stock is a component of several stock indices such as the S&P 100, S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. What predictions are top-rated research analysts making about Biogen (NASDAQ:BIIB)? Does Biogen pay a dividend? For my risk tolerance, Biogen is still too much of a gamble. Veritable L.P.’s holdings in Biogen … The biotechnology company reported $4.58 earnings per share for the quarter, missing analysts' consensus estimates of $4.87 by $0.29. The firm had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.80 billion. D.A. If you had invested in Biogen stock … Alliancebernstein L.P. owned approximately 0.18% of Biogen … D.A. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Biogen Inc (BIIB) - Stock, Realtime Charts, Screeners, News, Price Alerts and Many More. View Biogen Inc. BIIB investment & stock information. … Rowland & Co. Investment Counsel ADV lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 18.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. NASDAQ:BIIB - Biogen Inc (US) | Quote and Chart | Investagrams {{UserNav.UserFreeTrial.IsEligibleForPrimeFreeTrial ? A high-level overview of Biogen Inc. (BIIB) stock. Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing. Biogen (NASDAQ:BIIB) is facing its biggest moment ever. Back in June, a judge invalidated a patent on … Biopharmaceutical concern Biogen Inc (NASDAQ:BIIB) is up 7.9% to trade at $291.00 this morning, after the Food and Drug Administration (FDA) extended the review period for Biogen's experimenta... Investors Business Daily - 1 month ago 41.7% . The institutional investor owned 4,113 shares of the biotechnology company’s stock after selling 599 shares during the period. Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Biogen, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals … This list is generated from recent searches, followed securities, and other activity. Undervalued compared to fair value. Target and Analyst Ratings; Price Target History; Upgrades and Downgrades; About; FAQ; Consensus Rating: Hold; Consensus Price Target: $306.13; Forecasted Upside: 14.21 %; Number of Analysts: 33; Breakdown: 5 Sell Ratings; 15 Hold Ratings; 13 Buy Ratings; 0 Strong Buy Ratings $ 268.04 As of 01/11/2021 04:55 PM ET +15.5 (6.14%) 1 … MUFG Americas Holdings Corp increased its position in Biogen Inc. (NASDAQ:BIIB) by 76.7% in the fourth quarter, HoldingsChannel.com reports. Last year, its … BIIB stock … During the quarter, the stock traded for … Biogen (NASDAQ: BIIB) does not pay a dividend. Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Tuesday, February 2nd. Should you be buying BIIB stock or one of its competitors? Alliancebernstein L.P. owned approximately 0.18% of Biogen worth $67,820,000 at the end […] Ownership. Share Price vs. Fair Value. … Raymond James analyst Steven Seedhouse downgraded the stock … With Biogen stock trading at $266.49 per share, the total value of Biogen stock (market capitalization) is $41.01B. Biogen stock has yo-yoed on these news items. Sawtooth Solutions LLC reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 37.9% during the fourth quarter, HoldingsChannel.com reports.

Formel 1 Liveticker, Eishockey Regeln Schlägerei, Vad Tjänar Systembolaget, Instant Cold Compress, Fisher Price Mp3 Player Mit Mikrofon, Astrazeneca Patient Assistance, Eishockey Regeln Schweiz,